22157.jpg
Global Dermatology Diagnostic Devices Market Report 2021: Market Reached a Value of US$ 26.1 Billion in 2020 - Forecast to 2026
May 18, 2021 04:23 ET | Research and Markets
Dublin, May 18, 2021 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
22157.jpg
Insights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region
May 05, 2021 04:43 ET | Research and Markets
Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. According to this...
22157.jpg
Global Biomarkers 2021 Research Report - Technologies, Markets & Companies
April 30, 2021 04:23 ET | Research and Markets
Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Biomarkers - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report...
retro.jpg
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
April 21, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 16:05 ET | Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 25, 2021 07:00 ET | Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19
July 14, 2020 17:37 ET | Blue California Ingredients
Rancho Santa Margarita, Calif and Bedford, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Blue California, a science-based, innovative ingredient solution provider, has just filed for a patent on...
Oxford University Press Study Points to Effective and Inexpensive Infertility Treatment
February 17, 2016 13:32 ET | CellOxess
PRINCETON, N.J., Feb. 17, 2016 (GLOBE NEWSWIRE) -- An Oxford University Press study points to a promising treatment for male fertility that also reduces miscarriages in women. While men trying to...
Akers Bio logo
Akers Biosciences Commercializes New App-Enabled Tests for Health and Wellness Industry and Consumers
October 06, 2015 07:00 ET | Akers Biosciences Inc.
THOROFARE, N.J., Oct. 6, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare...
Akers Bio logo
Akers Biosciences Updates on New Rapid Breath Ketone and Oxidative Stress Tests for Health and Wellness Industry
June 16, 2015 09:41 ET | Akers Biosciences Inc.
THOROFARE, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of...